Bio-Reference Laboratories, Inc. is a clinical testing laboratory, which offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. The Company offers a range of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. It is focused on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional health care. It offers a list of chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology and other tissue analysis. It operates a clinical knowledge management service through its PSIMedica business unit. It also operates a Web-based connectivity portal solution for laboratories and physicians through its CareEvolve subsidiary. Its laboratory testing business consists of routine testing and esoteric testing.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryHealth Care Services
SectorN/A
Current SymbolNASDAQ:BRLI
Previous Symbol
CUSIP09057G60
Phone+1-201-7912186
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable
Bio-Reference Laboratories (NASDAQ:BRLI) Frequently Asked Questions
What is Bio-Reference Laboratories' stock symbol?
Bio-Reference Laboratories trades on the NASDAQ under the ticker symbol "BRLI."
How were Bio-Reference Laboratories' earnings last quarter?
Bio-Reference Laboratories Inc (NASDAQ:BRLI) announced its quarterly earnings data on Thursday, December, 18th. The medical research company reported $0.66 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.63 by $0.03. The medical research company earned $227.60 million during the quarter, compared to analyst estimates of $228.81 million. Bio-Reference Laboratories's revenue was up 18.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.40 earnings per share. View Bio-Reference Laboratories' Earnings History.
Has Bio-Reference Laboratories been receiving favorable news coverage?
Press coverage about BRLI stock has been trending very positive recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Bio-Reference Laboratories earned a coverage optimism score of 3.9 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
How do I buy shares of Bio-Reference Laboratories?
Shares of BRLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bio-Reference Laboratories' official website?
How can I contact Bio-Reference Laboratories?
Bio-Reference Laboratories' mailing address is 481 Edward H Ross Dr, ELMWOOD PARK, NJ 07407-3118, United States. The medical research company can be reached via phone at +1-201-7912186.
MarketBeat Community Rating for Bio-Reference Laboratories (NASDAQ BRLI)
MarketBeat's community ratings are surveys of what our community members think about Bio-Reference Laboratories and other stocks. Vote "Outperform" if you believe BRLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BRLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
